SRR975554
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- MYC_TARGETS_V1+0.470
- MYC_TARGETS_V2+0.460
- G2M_CHECKPOINT+0.450
- WNT_BETA_CATENIN_SIGNALING+0.420
- ALLOGRAFT_REJECTION+0.300
- INFLAMMATORY_RESPONSE+0.250
- TNFA_SIGNALING_VIA_NFKB+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.250
- HEDGEHOG_SIGNALING+0.230
Top 10 suppressed
- ADIPOGENESIS-0.430
- BILE_ACID_METABOLISM-0.420
- OXIDATIVE_PHOSPHORYLATION-0.420
- FATTY_ACID_METABOLISM-0.380
- XENOBIOTIC_METABOLISM-0.320
- PEROXISOME-0.310
- PROTEIN_SECRETION-0.260
- HEME_METABOLISM-0.250
- MYOGENESIS-0.240
- CHOLESTEROL_HOMEOSTASIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_WJ9H4NZZ | high-grade glioma | — | 0.802 |
| 2 | 7c4477a6-c744-412a-8571-bfb62f0dc714 | — | — | 0.797 |
| 3 | SRR934755 | — | — | 0.784 |
| 4 | SRR975566 | — | — | 0.784 |
| 5 | TCGA-68-8251-01A-11R-2296-07 | — | cohortSQ1 | 0.781 |
| 6 | TCGA-37-A5EM-01A-21R-A27Q-07 | — | cohortSQ1 | 0.762 |
| 7 | SRR8518263 | — | D | 0.754 |
| 8 | TCGA-CQ-A4CB-01A-11R-A24Z-07 | — | — | 0.749 |
| 9 | BS_H1ZS5FMZ | high-grade glioma | — | 0.748 |
| 10 | C3N-03093 | — | cohortA1 | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |